Baseline characteristics
| Characteristics | Patients (n = 30) |
|---|---|
| Age (years), median (range) | 61 (40–72) |
| Gender, n (%) | |
| Male | 28 (93.3) |
| Female | 2 (6.7) |
| ECOG performance status, n (%) | |
| 0 | 0 |
| 1 | 30 (100) |
| Location of the primary tumor, n (%) | |
| Upper | 6 (20.0) |
| Middle | 14 (46.7) |
| Lower | 9 (30.0) |
| Middle and lower | 1 (3.3) |
| Site of metastases, n (%) | |
| Brain | 0 |
| Liver | 7 (23.3) |
| Lung | 13 (43.3) |
| Bone | 2 (6.7) |
| Others | 27 (90.0) |
| Number of organs with metastases, n (%) | |
| 1 | 11 (36.7) |
| 2 | 13 (43.3) |
| ≥ 3 | 6 (20.0) |
| Prior cancer treatment, n (%) | |
| Surgery | 15 (50.0) |
| Radiotherapy | 18 (60.0) |
| Chemotherapy | 30 (100) |
| Differentiation, n (%) | |
| Well | 1 (3.3) |
| Moderate | 13 (43.3) |
| Poor | 6 (20.0) |
| Unknown | 10 (33.3) |
| Expression of EGFR, n (%) | |
| < 50% | 10 (33.3) |
| ≥ 50% | 20 (66.7) |
| Prior therapy lines, n (%) | |
| 1 | 20 (66.7) |
| 2 | 6 (20.0) |
| ≥ 3 | 4 (13.3) |
ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.